Division of Rare Cancer Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Department of Musculoskeletal Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Hum Cell. 2021 Nov;34(6):1911-1918. doi: 10.1007/s13577-021-00589-x. Epub 2021 Aug 12.
Myxofibrosarcoma (MFS) is an aggressive sarcoma with a highly complex karyotype. Complete resection is the only curative treatment for MFS because it is refractory to chemotherapy. To improve clinical outcomes, it is critical to develop novel treatments for MFS. Although patient-derived cell lines play a key role in cancer research, only 12 MFS cell lines have been reported to date, and considering the diversity of the disease, more cell lines need to be established. Hence, in the present study, we established a novel MFS cell line, NCC-MFS4-C1, using a surgically resected tumor tissue from a patient with MFS. NCC-MFS4-C1 cells exhibited copy number alterations similar to those of the original tumors and showed constant proliferation, spheroid formation, and aggressive invasion. By screening a drug library, we found that actinomycin D, bortezomib, docetaxel, eribulin, and romidepsin significantly reduced the proliferation of NCC-MFS4-C1 cells. Therefore, the NCC-MFS4-C1 cell line may be a useful resource for researching MFS.
黏液纤维肉瘤（MFS）是一种具有高度复杂核型的侵袭性肉瘤。完全切除是 MFS 的唯一治愈性治疗方法，因为它对化疗有抗性。为了改善临床结果，开发针对 MFS 的新疗法至关重要。尽管患者来源的细胞系在癌症研究中发挥着关键作用，但迄今为止仅报道了 12 种 MFS 细胞系，而且考虑到疾病的多样性，需要建立更多的细胞系。因此，在本研究中，我们使用 MFS 患者手术切除的肿瘤组织建立了一种新型 MFS 细胞系 NCC-MFS4-C1。NCC-MFS4-C1 细胞表现出与原始肿瘤相似的拷贝数改变，并表现出持续增殖、球体形成和侵袭性侵袭。通过筛选药物文库，我们发现放线菌素 D、硼替佐米、多西他赛、艾立布林和罗米地辛显著降低了 NCC-MFS4-C1 细胞的增殖。因此，NCC-MFS4-C1 细胞系可能是研究 MFS 的有用资源。
